Ulrich Julius

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

M Hanefeld, Sven Fischer, Ulrich Julius et al. · Diabetologia · 1996 · 879 citations · Full text

Diabetes Management, Diabetes Intervention Study, Cardiovascular Epidemiology +13

Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease

Josef Leebmann, E. Roeseler, Ulrich Julius et al. · Circulation · 2013 · 313 citations · Full text

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Antonio J. Vallejo‐Vaz, Christophe Stevens, Alexander R.M. Lyons et al. · The Lancet · 2021 · 285 citations · Full text

Family Medicine, Metabolic Syndrome, Lipid Disorder +10

Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease

E. Roeseler, Ulrich Julius, Franz Heigl et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2016 · 211 citations · Full text

Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Ioanna Gouni‐Berthold, Veronica J. Alexander, Qingqing Yang et al. · The Lancet Diabetes & Endocrinology · 2021 · 211 citations

Pharmacology, Pharmacotherapy, Medicine +1